<DOC>
	<DOCNO>NCT00284934</DOCNO>
	<brief_summary>This study introduce new optimization immunosuppressive regimen associate tacrolimus reduce dose enteric-coated mycophenolate sodium increase dose order slow renal function worsen prevent progression chronic allograft nephropathy , maintain efficacy , maintenance renal transplant recipient .</brief_summary>
	<brief_title>Enteric-coated Mycophenolate Sodium ( EC-MPS ) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus Stable Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Primary secondary kidney transplant Treatment mycophenolic acid ( MMF 1 g/d ECMPS 720 mg/d ) tacrolimus ( trough concentration [ C0 ] ≥ 5.5 ng/mL ) Creatinine clearance ≥ 30 mL/min &lt; 60 mL/min stable renal function Multiorgan recipients previous transplant organ different kidney Biopsy proven acute rejection treat acute rejection within last 3 month . Prescription mycophenolate mofetil 1 g/d mycophenolate sodium 720 mg/d due adverse event occurrence high dos administer Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Dose optimization</keyword>
	<keyword>immune suppressive regimen</keyword>
	<keyword>enteric-coated mycophenolate sodium</keyword>
	<keyword>EC-MPS</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>kidney</keyword>
	<keyword>transplant</keyword>
	<keyword>maintenance patient</keyword>
	<keyword>Renal transplantation maintenance</keyword>
</DOC>